Bile Duct Cancer Drugs Market Report Up to 2031: Visiongain Research Inc
January 12, 2022 10:00 ET
|
Visiongain Ltd
Visiongain has published a new report on Bile Duct Cancer Drugs Market Report to 2031. Profiles of Leading Bile Duct Cancer Drugs Market players, Regional and Leading National Market Analysis. PLUS,...
PROVECTUS BIOPHARMACEUTICALS EXPANDS GLOBAL PATENT PORTFOLIO FOR CANCER COMBINATION THERAPY
April 18, 2018 06:00 ET
|
Provectus Biopharmaceuticals Inc.
FOR IMMEDIATE RELEASE KNOXVILLE, TN, April 18, 2018 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com) (“Provectus” or the “Company”), a clinical-stage...
SNS FiRe Conference Names Atrin Pharmaceutical a 2016 FiReStarter Company
June 09, 2016 10:00 ET
|
Future In Review
SEATTLE, WA--(Marketwired - June 09, 2016) - Strategic News Service (SNS) has selected Atrin Pharmaceutical, Doylestown, PA, as a 2016 FiReStarter company to be featured at the 14th annual Future in...
Marshall Edwards Announces Additional Management Changes With Appointment of New Chief Financial Officer
June 17, 2010 09:00 ET
|
Marshall Edwards, Inc.
SAN DIEGO, CA--(Marketwire - June 17, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL), an oncology company focused on the clinical development of novel anti-cancer therapeutics, announced today...
Marshall Edwards' CEO to Present at Needham Healthcare Conference
June 03, 2010 08:00 ET
|
Marshall Edwards, Inc.
SYDNEY, AUSTRALIA and SAN DIEGO, CA--(Marketwire - June 3, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL), an oncology company focused on the clinical development of novel anti-cancer...
Marshall Edwards, Inc. Announces Grants Under Nasdaq Rule 5635
April 29, 2010 08:00 ET
|
Marshall Edwards, Inc.
SYDNEY, AUSTRALIA and SAN DIEGO, CA--(Marketwire - April 29, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHLD), a specialist oncology company focusing on the clinical development of novel anti-cancer...
Marshall Edwards Appoints New President and CEO
April 26, 2010 08:00 ET
|
Marshall Edwards, Inc.
SYDNEY, AUSTRALIA and SAN DIEGO, CA--(Marketwire - April 26, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHLD), an oncology company focused on the clinical development of novel anti-cancer therapeutics,...
Marshall Edwards, Inc. Announces Stockholder Approval and Implementation of 1:10 Reverse Stock Split
March 31, 2010 08:00 ET
|
Marshall Edwards, Inc.
NEW CANAAN, CT--(Marketwire - March 31, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL) (NASDAQ: MSHLD), a specialist oncology company focusing on the clinical development of novel anti-cancer...
Marshall Edwards, Inc. Announces Resignation of Christopher Naughton From Board of Directors
February 08, 2010 08:00 ET
|
Marshall Edwards, Inc.
SYDNEY, AUSTRALIA--(Marketwire - February 8, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL)
announced that Christopher Naughton had resigned as a member of the Board
of Directors effective February 5,...
Marshall Edwards, Inc. Appoints Acting CEO
December 01, 2009 00:01 ET
|
Marshall Edwards, Inc.
SYDNEY, AUSTRALIA and NEW CANAAN, CT--(Marketwire - December 1, 2009) - Novogen Limited
advises that CEO and Managing Director Christopher Naughton will cease his
employment with the Company from...